OpGen (NASDAQ:OPGN) stock is taking off today following a couple of pieces of news from the precision medicine company.

The first bit of news worth mentioning is a The company has received an advanced payment of 750,000 euros for the sale of certain Unyvero A50 systems by Curetis to a strategic partner.

OpGen is working with a strategic partner on this sale, which includes Curetis and the company’s subsidiary Ares Genetics. To go along with this, the strategic partner has the option to acquire more Unyvero A50 systems as part of the deal.

OpGen also announced a Preferred Stock Purchase Agreement that investors will want to know about. The company has signed an agreement with a certain investor for them to acquire 1,000 shares priced at $1,000 each.

That deal will see the company generate gross proceeds of $1 million. This private placement was made as OpGen continues negotiations with the investors for a potential strategic transaction between the two.

All of this news brings with it heavy trading of OPGN stock on Thursday. As of this writing, more than 13 million shares of the stock have changed hands. That’s a massive surge in trading volume over its daily average of about 2.3 million shares.

OPGN stock is up 539.9% as of Thursday morning.

‍

‍

Disclaimer: This content is made for entertainment purposes only. This is not financial advice.